Dr. Zarychanski is a Critical Care physician, Hematologist, and Clinician-Scientist at the University of Manitoba and CancerCare Manitoba. His research focuses on the hematologic aspects of critical illness. In collaboration with the Canadian Critical Care Trials Group, his major program of research is studying unfractionated heparin in septic shock – a program that has now culminated into an international randomized controlled trial. Other research programs evaluate the use of IVIG and plasma exchange in septic shock and the ability of tranexamic to reduce transfusion in major non-cardiac surgery. He currently co-leads two international trials evaluating anticoagulation strategies in COVID-19.